JNJ-64417184 + famotidine

**JNJ-64417184 + famotidine** is a combination of two distinct agents. **JNJ-64417184** is an investigational antiviral small molecule developed for the treatment of respiratory syncytial virus (RSV) infection by inhibiting the genetic multiplication of the virus, thereby slowing the production of new virus particles. **Famotidine** is a marketed H2-receptor antagonist that reduces gastric acid secretion. This combination is used in a clinical pharmacology setting to assess drug-drug interactions, specifically how acid-reducing agents (like famotidine) affect the pharmacokinetics and safety of JNJ-64417184 when coadministered. The primary indication for this investigative pairing is RSV infection in healthy adults as part of Phase 1 clinical studies[1][2].